Acquisition Primes Airborne For Claims Overhaul
This article was originally published in The Tan Sheet
Executive Summary
GF Capital Private Equity Fund is overhauling Airborne Inc. to steer the firm clear of the regulatory issues that have plagued it
You may also be interested in...
Schiff Nutrition Enlists Airborne For Sortie Into Immune Support
The $150 million price represents more than twice Airborne’s approximately $70 million in annual net revenues for supplements marketed to strengthen immune support. The acquisition from GF Capital follows Pfizer’s recent foray into the immune support space by buying the maker of Emergen-C products.
Schiff Nutrition Enlists Airborne For Sortie Into Immune Support
The $150 million price represents more than twice Airborne’s approximately $70 million in annual net revenues for supplements marketed to strengthen immune support. The acquisition from GF Capital follows Pfizer’s recent foray into the immune support space by buying the maker of Emergen-C products.
FTC Settlement Looks To Ground Airborne Claims
Under a settlement with the Federal Trade Commission announced Aug. 14, the maker of Airborne dietary supplement products must cease unsubstantiated health-related claims and contribute up to $6.5 million to an existing consumer redress fund